Advancements in Custom Biopharmaceutical DevelopmentClara Prieto2024-07-08T13:23:58+02:00June 17, 2024|Read More
Accelerating Biologics Development: mAbxience’s “Gene to Biologics Drug Substance (BDS) in 12 Months” ProgramMiguel Martínez-Cava2024-05-29T11:51:27+02:00May 29, 2024|Read More
The Future of Biosimilars: Trends and PredictionsMiguel Martínez-Cava2024-02-26T08:56:52+01:00February 26, 2024|Read More
Improving Drug Development: The Strategic Value of CDMO PartnershipsMiguel Martínez-Cava2024-02-12T10:05:10+01:00February 12, 2024|Read More
The Evolution of Biopharmaceutical ManufacturingMiguel Martínez-Cava2024-01-22T08:38:03+01:00January 22, 2024|Read More
Celebrating Emmanuelle Lepine’s Legacy of Excellence at mAbxienceMiguel Martínez-Cava2024-01-15T07:54:41+01:00January 15, 2024|Read More
Boosting biologics and Contract Manufacturing at mAbxience facilitiesMiguel Martínez-Cava2023-04-03T09:26:50+02:00April 3, 2023|Read More
HK inno.N licenses in mAbxience’s denosumab biosimilarMiguel Martínez-Cava2023-01-25T10:46:18+01:00January 25, 2023|Read More
Fresenius Kabi completes majority stake acquisition of mAbxience Holding S.L., significantly enhancing presence in high-growth biopharmaceuticals marketMiguel Martínez-Cava2022-08-01T17:18:20+02:00August 1, 2022|Read More
